FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2564651636> ?p ?o ?g. }

• W2564651636 abstract "Abstract Abstract 3578 Decitabine (DAC) is successfully used for treatment of patients (pts) with myelodysplastic syndromes and AML. Following cellular uptake, DAC is thought to be activated to DAC-TP and incorporated into DNA. The DAC-TP/DNA complex binds and inactivates DNA methyltransferases (DNMTs), thereby leading to hypomethylation and re-expression of epigenetically silenced tumor suppressor genes and ultimately anti-leukemia activity. However, direct evidence of in vivo DAC-TP occurrence in DAC-treated pts has been difficult to demonstrate due to a lack of suitable validated analytical methodology. Thus, we developed and validated a sensitive and specific LC-MS/MS method for quantification of DAC-TP. The assay exhibited excellent accuracy and precision. The accuracy values were 83.7–109.4%, as determined by calculating the percentage of measured DAC-TP relative to the respective nominal concentrations (50, 500 and 5,000 nM) of the quality control samples. The within-day coefficients of variation (CVs) were 19.9 % (n=6) at 50 nM and 4.7–7.0 % between 500–5,000 nM; the between-day CVs (n=3) were 15.2 % at 50 nM and 7.5–10.2 % between 500–5,000 nM. Following DAC treatment, we detected DAC-TP in parental and DAC-resistant MV4–11, and in THP-1 and FDC-P1/Kitmut cells (in vitro); and in bone marrow (BM) and spleen of normal and FDC-P1/Kitmut-driven AML mice (in vivo). DAC-TP reached peak levels (0.8, 1.4 and 0.5 pmol/106 cells) in 1–4 hours and declined to 20 % of its peak concentration after 24 hours incubation with 2.5 μM DAC in MV4–11, THP-1 and FDC-P1/Kitmut cells, respectively. Inhibition of hENT1 that mediates DAC transport into the cells and dCK that phosphorylates DAC into DAC-TP by NBTI and 2-thio-2′-deoxycytidine, respectively, significantly inhibited DAC-TP accumulation in AML cells. DAC-TP decay was instead blocked by tetrahydrouridine (THU)-induced inhibition of CDA, the catabolizing enzyme for cytidine and deoxycytidine and analogs. Consistent with these results, low dCK and hENTs but not CDA expression were detected in DAC-resistant MV4–11 cells, which showed 60 % decrease in DAC-TP levels as compared to their parental counterparts. DAC/DAC-TP-mediated downregulation of DNMT proteins (preferentially DNMT1 and DNMT3a) was also demonstrated in the AML cells even at DAC-TP concentrations as low as 0.1–1.3 pmol/106 cells in vitro after 4 hours DAC incubation. In the in vivo experiments, DAC-TP levels in leukemic mice were comparable to that in normal C57BL/6 mice, 0.3 pmol/106 cells in BM and 199.2 pmol/g tissue in spleen at 4-hours and 0.2 pmol/106 cells in BM and 165.3 pmol/g tissue in spleen at 24-hours following an i.v. bolus of 6.5 mg/kg DAC. In BM of leukemic mice, not only DNMT1 and DNMT3a but also DNMT3b protein expression reduced 80 % (DNMT3a) or diminished (DNMT1 and DNMT3b). The clinical applicability of this method was proven by measuring DAC-TP level in BM and blood mononuclear cells (PBMC) from AML pts treated with a 10-day regimen of DAC given 20 mg/m2/day i.v. over 1 hour. In BM samples, the mean DAC-TP levels were 0.8 ± 0.6 (Day 1) and 0.9 ± 0.5 pmol/106 cells (Day∼5) in complete responsive (CR) pts (n=4); and 0.4 ± 0.3 (Day 1) and 0.12 ± 0.02 pmol/106 cells (Day∼5) in non-responsive (NR) pts (n=3). In PBMC samples, the mean DAC-TP levels were 0.5 ± 0.2 (Day 1) and 1.2 ± 0.4 pmol/106 cells (Day∼5) in CR pts (n=3); and 0.02 ± 0.02 (Day 1) and 0.21 ± 0.04 pmol/106 cells (Day∼5) in NR pts (n=3). These data suggested that higher levels are seemingly associated with clinical response, but a larger number of pts need to be tested. In conclusion, monitoring the intracellular concentration of DAC-TP is feasible, and DAC-TP levels correlate with DNMT downregulation and may serve as a novel pharmacological endpoint for designing more effective DAC-based regimens. Disclosures: No relevant conflicts of interest to declare." @default.
• W2564651636 created "2017-01-06" @default.
• W2564651636 creator A5000921376 @default.
• W2564651636 creator A5004233773 @default.
• W2564651636 creator A5004524654 @default.
• W2564651636 creator A5007251823 @default.
• W2564651636 creator A5012262072 @default.
• W2564651636 creator A5015548619 @default.
• W2564651636 creator A5021452379 @default.
• W2564651636 creator A5023917898 @default.
• W2564651636 creator A5026394330 @default.
• W2564651636 creator A5031040416 @default.
• W2564651636 creator A5047855185 @default.
• W2564651636 creator A5051480539 @default.
• W2564651636 creator A5051619378 @default.
• W2564651636 creator A5056111187 @default.
• W2564651636 creator A5056314507 @default.
• W2564651636 creator A5058508244 @default.
• W2564651636 creator A5060959458 @default.
• W2564651636 creator A5086687120 @default.
• W2564651636 date "2012-11-16" @default.
• W2564651636 modified "2023-09-27" @default.
• W2564651636 title "Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML)" @default.
• W2564651636 doi "https://doi.org/10.1182/blood.v120.21.3578.3578" @default.
• W2564651636 hasPublicationYear "2012" @default.
• W2564651636 type Work @default.
• W2564651636 sameAs 2564651636 @default.
• W2564651636 citedByCount "0" @default.
• W2564651636 crossrefType "journal-article" @default.
• W2564651636 hasAuthorship W2564651636A5000921376 @default.
• W2564651636 hasAuthorship W2564651636A5004233773 @default.
• W2564651636 hasAuthorship W2564651636A5004524654 @default.
• W2564651636 hasAuthorship W2564651636A5007251823 @default.
• W2564651636 hasAuthorship W2564651636A5012262072 @default.
• W2564651636 hasAuthorship W2564651636A5015548619 @default.
• W2564651636 hasAuthorship W2564651636A5021452379 @default.
• W2564651636 hasAuthorship W2564651636A5023917898 @default.
• W2564651636 hasAuthorship W2564651636A5026394330 @default.
• W2564651636 hasAuthorship W2564651636A5031040416 @default.
• W2564651636 hasAuthorship W2564651636A5047855185 @default.
• W2564651636 hasAuthorship W2564651636A5051480539 @default.
• W2564651636 hasAuthorship W2564651636A5051619378 @default.
• W2564651636 hasAuthorship W2564651636A5056111187 @default.
• W2564651636 hasAuthorship W2564651636A5056314507 @default.
• W2564651636 hasAuthorship W2564651636A5058508244 @default.
• W2564651636 hasAuthorship W2564651636A5060959458 @default.
• W2564651636 hasAuthorship W2564651636A5086687120 @default.
• W2564651636 hasConcept C104317684 @default.
• W2564651636 hasConcept C126322002 @default.
• W2564651636 hasConcept C150194340 @default.
• W2564651636 hasConcept C150903083 @default.
• W2564651636 hasConcept C153911025 @default.
• W2564651636 hasConcept C185592680 @default.
• W2564651636 hasConcept C190727270 @default.
• W2564651636 hasConcept C207001950 @default.
• W2564651636 hasConcept C2776012956 @default.
• W2564651636 hasConcept C2776239401 @default.
• W2564651636 hasConcept C2778461978 @default.
• W2564651636 hasConcept C2778729363 @default.
• W2564651636 hasConcept C2779282312 @default.
• W2564651636 hasConcept C2780007613 @default.
• W2564651636 hasConcept C2780235182 @default.
• W2564651636 hasConcept C33288867 @default.
• W2564651636 hasConcept C502942594 @default.
• W2564651636 hasConcept C552990157 @default.
• W2564651636 hasConcept C55493867 @default.
• W2564651636 hasConcept C71924100 @default.
• W2564651636 hasConcept C86803240 @default.
• W2564651636 hasConcept C91965660 @default.
• W2564651636 hasConceptScore W2564651636C104317684 @default.
• W2564651636 hasConceptScore W2564651636C126322002 @default.
• W2564651636 hasConceptScore W2564651636C150194340 @default.
• W2564651636 hasConceptScore W2564651636C150903083 @default.
• W2564651636 hasConceptScore W2564651636C153911025 @default.
• W2564651636 hasConceptScore W2564651636C185592680 @default.
• W2564651636 hasConceptScore W2564651636C190727270 @default.
• W2564651636 hasConceptScore W2564651636C207001950 @default.
• W2564651636 hasConceptScore W2564651636C2776012956 @default.
• W2564651636 hasConceptScore W2564651636C2776239401 @default.
• W2564651636 hasConceptScore W2564651636C2778461978 @default.
• W2564651636 hasConceptScore W2564651636C2778729363 @default.
• W2564651636 hasConceptScore W2564651636C2779282312 @default.
• W2564651636 hasConceptScore W2564651636C2780007613 @default.
• W2564651636 hasConceptScore W2564651636C2780235182 @default.
• W2564651636 hasConceptScore W2564651636C33288867 @default.
• W2564651636 hasConceptScore W2564651636C502942594 @default.
• W2564651636 hasConceptScore W2564651636C552990157 @default.
• W2564651636 hasConceptScore W2564651636C55493867 @default.
• W2564651636 hasConceptScore W2564651636C71924100 @default.
• W2564651636 hasConceptScore W2564651636C86803240 @default.
• W2564651636 hasConceptScore W2564651636C91965660 @default.
• W2564651636 hasLocation W25646516361 @default.
• W2564651636 hasOpenAccess W2564651636 @default.
• W2564651636 hasPrimaryLocation W25646516361 @default.
• W2564651636 hasRelatedWork W2081778277 @default.
• W2564651636 hasRelatedWork W2347334090 @default.
• W2564651636 hasRelatedWork W2487532577 @default.
• W2564651636 hasRelatedWork W2551607392 @default.
• W2564651636 hasRelatedWork W2553914489 @default.
• W2564651636 hasRelatedWork W2559771466 @default.

• next